Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23816967 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
Conditions: Carcinoma, Non-Small-Cell Lung;   Adenocarcinoma
Interventions: Drug: Pemetrexed;   Drug: BIBW 2992;   Drug: Cisplatin

Indicates status has not been verified in more than two years